VTGN VistaGen Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VTGN

Price (delayed)

$4.5

Market cap

$121.61M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.43

Enterprise value

-$2.69M

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and ...

Highlights
VTGN's quick ratio has surged by 135% since the previous quarter
VistaGen Therapeutics's EPS has soared by 64% YoY and by 26% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.vistagen.com
Peers: OMER OMGA

Key stats

What are the main financial stats of VTGN
Market
Shares outstanding
27.03M
Market cap
$121.61M
Enterprise value
-$2.69M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.99
Price to sales (P/S)
126.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-2.58
Earnings
Revenue
$1.04M
EBIT
-$32.06M
EBITDA
-$31.51M
Free cash flow
-$26.12M
Per share
EPS
-$3.43
Free cash flow per share
-$0.89
Book value per share
$4.56
Revenue per share
$0.04
TBVPS
$4.46
Balance sheet
Total assets
$131.07M
Total liabilities
$7.78M
Debt
$2.25M
Equity
$123.28M
Working capital
$123.95M
Liquidity
Debt to equity
0.02
Current ratio
30.76
Quick ratio
30.39
Net debt/EBITDA
3.95
Margins
EBITDA margin
-3,022.7%
Gross margin
100%
Net margin
-3,076.6%
Operating margin
-3,252.5%
Efficiency
Return on assets
-61.3%
Return on equity
-72.1%
Return on invested capital
-922.4%
Return on capital employed
-25.3%
Return on sales
-3,076.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VTGN stock price

How has the VistaGen Therapeutics stock price performed over time
Intraday
2.04%
1 week
-5.26%
1 month
-16.36%
1 year
-96.33%
YTD
-12.45%
QTD
-14.77%

Financial performance

How have VistaGen Therapeutics's revenue and profit performed over time
Revenue
$1.04M
Gross profit
$1.04M
Operating income
-$33.9M
Net income
-$32.07M
Gross margin
100%
Net margin
-3,076.6%
The net income has increased by 50% year-on-year and by 10% since the previous quarter
The company's operating income rose by 47% YoY and by 5% QoQ
The company's net margin rose by 30% QoQ
The gross profit has grown by 29% from the previous quarter

Growth

What is VistaGen Therapeutics's growth rate over time

Valuation

What is VistaGen Therapeutics stock price valuation
P/E
N/A
P/B
0.99
P/S
126.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-2.58
VistaGen Therapeutics's EPS has soared by 64% YoY and by 26% from the previous quarter
The price to book (P/B) is 42% lower than the last 4 quarters average of 1.7
VistaGen Therapeutics's revenue has increased by 29% QoQ

Efficiency

How efficient is VistaGen Therapeutics business performance
The ROE has soared by 62% from the previous quarter and by 54% YoY
The company's return on invested capital has surged by 56% YoY and by 3.6% QoQ
The company's return on assets has surged by 53% QoQ and by 51% YoY
VistaGen Therapeutics's ROS has increased by 30% from the previous quarter

Dividends

What is VTGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VTGN.

Financial health

How did VistaGen Therapeutics financials performed over time
VTGN's quick ratio has surged by 135% since the previous quarter
The current ratio has soared by 129% from the previous quarter
The company's debt is 98% lower than its equity
VTGN's debt to equity has dropped by 87% year-on-year and by 71% since the previous quarter
The company's debt fell by 28% YoY and by 5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.